We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
TÜRKBİO veritabanında kayıtlı biyolojik ilaç tedavisi kullanan ankilozan spondilit hastalarının değerlendirilmesi.
- Authors
Güllüoðlu, Hacer; Çetin, Pýnar; Sarý, Ýsmail; Birlik, Merih; Önen, Fatoþ; Akkoç, Nurullah
- Abstract
Objective: TURKBIO registry is a Turkish version of Danish DANBIO rheumatologic database. The primary aim of this database is to collect clnical and demographic data from rheumatic patients receiving biological agents. In this study we aimed to collect data from ankylosing spondylitis (AS) patients receiving biological medications who were registered in TURKBIO database. Methods: All AS patients receiving biological therapies registered in TURKBIO database between October 2011 and September 2012 were included in the study. Demographic and clinical data including age, sex, and disease duration, the name of the medications used, the date of starting to use biological drug, frequency and dose of biological drugs, nonsteroidal anti-inflammatory drugs and analgesics, BASFI, BASDAI, BASMI, smoking habit, date and reason of discontinuing to use drug were collected, and they were analyzed by appropriate statistical methods. Results: In our study group, there were 220 AS patients according to the modified New York criteria. The median age of the patients was 39 (range: 14-73) years. Male-female sex distribution was 73/27%. Median disease duration was 15 (range: 1-55) years. There were totally 1579 visits for 220 patients. The median visit per patient was 6 (range: 1-39). The median biologic usage was calculated 489 (range: -20-3160) days when biological commencement day was considered as day zero. The distributions of biological therapies were as follows: infliximab (40.5%), etanercept (33.6%), adalimumab (25%) and anakinra (0.9%). The BASFI and BASDAI values were significantly reduced after biological treatment (p<0.05). Inefficacy and lost-to-follow up were the most frequent reasons for discontinuing the biotherapy. Conclusion: Results from TURKBIO registry suggest that biological therapies are effective in controlling disease activity and maintaining the function. It also seems that these therapies have reasonable safety profile.
- Publication
RAED Journal / RAED Dergisi, 2014, Vol 6, Issue 1, p13
- ISSN
1301-4021
- Publication type
Article
- DOI
10.2399/raed.14.46220